Hepatocytes are a key target for treatment of inborn errors of metabolism, dyslipidemia and coagulation disorders. The development of potent expression cassettes is a critical target to improve the therapeutic index of gene transfer vectors.
Introduction
Parenchymal liver cells (PC) or hepatocytes are a key target for treatment of inborn errors of metabolism, dyslipidemia and coagulation disorders. Clinical translation of gene transfer requires the development of technologies with a sufficiently high therapeutic index. The development of potent expression cassettes is a critical target to improve the therapeutic index of gene transfer vector systems. Optimalization of transgene expression can be achieved by modulating all levels of expression including transcription, post-transcriptional modification of RNA, RNA export, RNA stability and translation. Transcriptional targeting by use of hepatocyte-specific expression cassettes may lead to immunological ignorance or tolerance for the transgene product. [1] [2] [3] Expression cassettes for hepatocyte-directed transfer have been improved by using new promoterenhancer combinations, [3] [4] [5] [6] [7] [8] [9] inclusion of introns 5,10-13 and inclusion of additional transcriptional sequences like scaffold matrix-attached regions (SMAR) and hepatic control regions (HCR). 12, [14] [15] [16] [17] [18] However, because different gene transfer vectors, different doses and different transgenes were used in these studies, direct comparative data for different expression cassettes are often lacking and hamper the interpretation of existing literature.
A major limitation for the use of plasmids in nonviral gene transfer is transcriptional silencing in vivo caused by bacterial sequences covalently linked to the expression cassette. 19, 20 Minicircles are devoid of bacterial sequences and may induce persistent transgene expression. 19, 21 Previous studies of our group comparing the potency of different expression cassettes have shown that the combination of the 1.5 kb hepatocyte-specific human a 1 -antitrypsin (AT) promoter and four copies of the human apo E enhancer (E 4 ) results in superior expression levels compared to the ubiquitously active cytomegalovirus (CMV) promoter, the ubiquitously active murine U1b small nuclear RNA promoter and the combination of the apolipoprotein (apo) A-I or apo C-II promoter and four copies of the human apo E enhancer. 1, 8, [22] [23] [24] In these studies, the promoter was placed upstream of the four exons and three introns of the human apo A-I gene. C57BL/6 mice are tolerant for human apo A-I following transfer with adenoviral vectors containing hepatocytespecific expression cassettes. 1, 22, 23 The objective of the current study was to directly compare 22 hepatocytespecific expression cassettes containing a human apo A-I transgene in C57BL/6 mice. For each of these expression cassettes, hydrodynamic gene transfer of plasmids and gene transfer with the corresponding E1E3E4-deleted adenoviral vectors were performed. In the present study, the DC172 promoter, consisting of a 890 bp human AT promoter and two copies of the 160 bp a 1 -microglobulin enhancer, combined with two copies of the 774 bp hepatic control region-1 (HCR-1), is the most potent expression cassette both in the setting of adenoviral and hydrodynamic transfer. Hydrodynamic gene transfer of minicircles containing these transcriptional regulatory sequences persistently induces physiological human apo A-I and human factor IX (FIX) levels in C57BL/6 mice.
Results
The combination of the DC172 promoter and two copies of the hepatic control region-1 results in the highest transgene expression levels after hydrodynamic and adenoviral transfer
The construct containing the 1.5 kb human AT promoter upstream of the genomic human apo A-I sequence (gA-I) and four copies of the 154 bp human apo E enhancer has previously been shown to constitute the most potent expression cassette in studies by Van Linthout et al. 8, 24 This construct (AT.gA-I.E 4 ) was the reference construct in the current study. To further optimize transgene expression following hepatocyte-directed transfer, the reference construct was compared with 21 additional hepatocytespecific expression cassettes in C57BL/6 mice following hydrodynamic transfer of 70 mg of plasmids or gene transfer with 5 Â 10 10 particles of E1E3E4-deleted adenoviral vectors. Figure 1 shows the kinetics of human apo A-I expression after hydrodynamic and adenoviral transfer with the reference construct. Whereas peak expression following hydrodynamic and adenoviral transfer were similar, expression levels at day 35 following hydrodynamic transfer were 12-fold (Po0.0001) lower than after transfer with E1E3E4-deleted adenoviral vectors. Peak human apo A-I expression after hydrodynamic transfer of conventional plasmids, peak expression after adenoviral transfer and expression at day 35 after adenoviral transfer for all 22 constructs evaluated in this study are represented in Table 1 . Human apo A-I expression at day 35 after hydrodynamic transfer of plasmids was below 15 mg per 100 ml for all constructs (data not shown). Figure 2 shows the linear regression graph for the peak expression after hydrodynamic gene transfer as independent variable and the peak human apo A-I expression ( Figure  2a For constructs containing the 1.5 kb human AT promoter and four copies of the human apo E enhancer (E 4 ), transgene expression was compared for the human apo A-I cDNA sequence, the cDNA sequence preceded by a 5 0 -untranslated region (UTR) containing the first intron of the human apo A-I gene (A-I intron) or a truncated first intron of the factor IX gene (FIX intron) and gA-I (Table 1) . Human apo A-I expression levels were significantly higher when the first intron of human apo A-I or FIX gene was incorporated in the expression cassette ( Table 1) . The presence of all three introns of the human apo A-I gene in the construct AT.gA-I.E 4 resulted in a significant further increment of expression levels compared to the constructs AT.A-I intron.cDNA.E 4 and AT.FIX intron.cDNA.E 4 . All further experiments were performed with constructs containing the genomic human gA-I. The presence of the 2.0 kb SMAR from the 5 0 region of the human interferon-b gene in the construct E 4 .AT.gA-I.SMAR did not increase expression levels following adenoviral transfer (Table 1) . Subsequently, the reference construct (AT.gA-I.E 4 ) was compared with constructs containing the synthetic liverspecific promoter (LSP), the DC190 promoter and the DC172 promoter. These three promoters were combined with zero, two or four copies of the 154 bp human apo E enhancer. Compared to the reference construct, expression cassettes containing the LSP promoter resulted in significantly lower expression levels whereas constructs containing the DC190 promoter induced equivalent or lower transgene expression ( Table 1 ). The combination of the DC172 promoter and four copies of the human apo E enhancer resulted in superior expression levels after adenoviral transfer compared to the reference construct.
The apo E enhancer is part of the HCR-1. We evaluated whether the substitution of apo E enhancers by one or multiple copies of HCR-1 results in improved expression levels in constructs containing the AT or DC172 promoter ( Table 1 ). The combination of the DC172 promoter and two copies of HCR-1 (DC172.gA-I.HCR 2 ) resulted in 1.7-(Po0.01) and 2.9-fold (Po0.01) higher peak human apo A-I levels after hydrodynamic ( 
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AdDC172.gA-I.HCR 2 was 2.6-fold (Po0.01) higher than after transfer with the reference vector AdAT.gA-I.E 4 ( Table 1 ). The combination of the DC172 promoter and four copies of HCR-1 resulted in equivalent expression levels compared to the DC172 promoter combined with two copies of HCR-1 ( Table 1) . 180±9.8 280±11** 250±20** Abbreviations: A-I intron, 5 0 UTR of human apo A-I gene containing the first intron; AT, 1.5 kb human a 1 -antitrypsin promoter; cDNA, human apo A-I cDNA; DC172, DC172 promoter consisting of a 890 bp human a 1 -antitrypsin promoter and two copies of the 160 bp a 1 -microglobulin enhancer; DC190, DC190 promoter containing a 520 bp human albumin promoter and two copies of the 99 bp prothrombin enhancer; FIX intron, 5 0 UTR containing factor IX intron; gA-I, genomic human apo A-I sequence; HCR, hepatic control region-1; LSP, liver-specific promoter consisting of the 475 bp thyroid hormone-binding globulin promoter and two copies of the 96 bp bikunin/a 1 -microglobulin enhancer. To compare intrahepatic transgene DNA kinetics following hydrodynamic transfer of minicircles and adenoviral transfer, PC and nonparenchymal liver cells (NPC) were separated by collagenase perfusion and Nycodenz centrifugation at 1, 24 h and 35 days after transfer ( Table 2 ). The initial transgene DNA levels in liver PC and NPC were significantly higher after hydrodynamic transfer with 20 mg of mcDC172.gA-I.HCR 2 than after transfer with 5 Â 10 10 particles of AdDC172.gA-I.HCR 2 . There was no significant drop of the transgene DNA copy number in the PC between 24 h and day 35 after adenoviral transfer. The copy number in the PC at 24 h was 5.8-fold (Po0.01) higher after hydrodynamic transfer with 20 mg of mcDC172.gA-I.HCR 2 than after transfer with Ad-DC172.gA-I.HCR 2 , but an 8.0-fold (Po0.01) decrease occurred between 24 h and 35 days after hydrodynamic transfer resulting in similar transgene DNA levels than after adenoviral transfer at day 35.
Comparison of liver inflammation following hydrodynamic transfer of minicircles and adenoviral transfer expressing human apo A-I Adenoviral and hydrodynamic transfer F Jacobs et al different time points after adenoviral and hydrodynamic transfer. The number of infiltrating neutrophils per mm 2 was 1.5-(Po0.02) and 3.8-fold (Po0.0001) higher at 6 and 24 h, respectively, after hydrodynamic transfer with minicircles than after adenoviral transfer and returned to baseline at later time points for both hydrodynamic and adenoviral transfer (Figure 4a ). Figure 4b illustrates that the number of infiltrating CD3-positive T lymphocytes was significantly higher at 24 h and at day 3 after hydrodynamic transfer compared to adenoviral transfer whereas at day 7 and at day 10 the reverse was observed. The number of CD3-positive T lymphocytes returned to baseline at day 21 after transfer for both hydrodynamic and adenoviral transfer (Figure 4b ).
Absence of episomal replication following hydrodynamic gene transfer with minicircles containing an SMAR and the SV40 origin of replication To evaluate whether the SV40 origin of replication and the human b-interferon SMAR may confer episomal replication to minicircles, hydrodynamic gene transfer was performed with 20 mg of minicircles containing the DC172 promoter upstream of gA-I, the human b-interferon SMAR, two copies of HCR-1 and the SV40 origin of replication (mcDC172.gA-I.SMAR.HCR 2 .SV40ori). Figures 5a and b show that a 70% partial hepatectomy at day 6 after hydrodynamic transfer with 20 mg of mcDC172.gA-I.HCR 2 and mcDC172.gA-I.SMAR.HCR 2 .SV40ori, respectively, resulted in a sharp drop of human apo A-I expression levels. Compared to mice without partial hepatectomy, the human apo A-I transgene DNA copy number at day 35 after transfer in mice with partial hepatectomy at day 6 was 5.4-(Po0.01) and 5.5-fold (Po0.01) lower for mcDC172.gA-I.HCR 2 and mcDC172.gA-I.SMAR.HCR 2 . SV40ori, respectively (Table 3) .
Discussion
The main findings of the current study on hepatocytedirected gene transfer are that (1) the DC172 promoter is more potent than the 1.5 kb human AT, the LSP and the DC190 promoters; (2) the combination of the DC172 promoter and two copies of the human HCR-1 results in the highest human apo A-I levels after both hydrodynamic and adenoviral gene transfer; (3) hydrodynamic gene transfer of minicircles containing the most potent expression cassette results in sustained physiological levels of human apo A-I and human FIX and (4) hydrodynamic gene transfer of minicircles containing the human b-interferon SMAR and the SV40 origin of replication does not result in episomal replication of the minicircles following partial hepatectomy.
Ubiquitously active promoters such as the human cytomegalovirus immediate early gene promoter (CMV) and the elongation factor 1-a promoter have often been used to induce high levels of transgene expression. 25 However, expression in antigen-presenting cells potentiates adaptive immune responses and this may be circumvented by the use of hepatocyte-specific promoters. [1] [2] [3] In addition, we have previously shown that the combination of the AT promoter and four copies of the human apo E enhancer results in superior expression levels compared to the ubiquitously active CMV promoter. 1, 8, 23 The most frequently used hepatocyte-specific promoters, with or without fusion of one or two heterologous enhancer elements, are the human AT promoter, 4, 12, 26, 27 the albumin promoter 28, 29 and the LSP promoter. 3, 7, 9 In this direct comparative study using hydrodynamic and adenoviral gene transfer, we show that the DC172 promoter, consisting of a 890 bp human AT promoter and two copies of the 160 bp a 1 -microglobulin enhancer, combined with two or four copies of the HCR-1 3 0 of the transgene, constitutes the most potent expression cassette. The a 1 -microglobulin/bikunin precursor promoter is weak and ubiquitously active, but expression in PC is potently increased by a hepatocytespecific enhancer located 2.7 kb downstream of the promoter. [30] [31] [32] Since it is unlikely that there are major differences in the transcriptional activity of the 1.5 kb and the 890 bp AT promoters, our results suggest that the effect of two copies of the a 1 -microglobulin enhancer in the 
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F Jacobs et al DC172 promoter is equivalent to the effect of four copies of the apo E enhancer (DC172.gA-I versus AT.gA-I.E 4 ). The combination of two copies of the a 1 -microglobulin enhancer and four copies of the human apo E enhancer results in a significant further increment of expression levels, but the highest expression levels are observed when four human apo E enhancers are replaced by two or four copies of the HCR-1. The HCR-1, previously described by Simonet et al., 33 contains the 154 bp apo E enhancer. 34 Our data clearly indicate that part of the effect of HCR-1 is mediated by sequences in HCR-1 different from the apo E enhancer.
The potentiation of transgene expression by introns 5, [10] [11] [12] [13] is confirmed in the current study. All constructs in the current study contain an intron in the SV40 splice/polyadenylation site. The incorporation of an additional intron in the construct by inclusion of the first intron of the apo A-I gene or a truncated FIX intron 5 0 of the cDNA coding sequence of apo A-I increases transgene expression more than twofold. Using the genomic human gA-I, containing three introns, it induced an incremental more than twofold increase of human apo A-I levels, suggesting that preservation of the complete intron-exon structure may be important to maximize transgene expression. Although the exact mechanism of the stimulatory effect of introns is not known, intronic sequences or the process of splicing itself may promote 3 0 RNA processing, facilitate the export of messenger RNA from the nucleus to the cytoplasm 35 and promote translation. [36] [37] [38] The correlation between peak human apo A-I expression after hydrodynamic gene transfer and human apo A-I expression at day 35 transfer with the corresponding adenoviral vectors was 0.83. This indicates that evaluation of expression cassettes using hydrodynamic transfer may be a suitable strategy to predict expression levels following other modes of gene transfer. Bacterial DNA sequences on conventional plasmids cause transcriptional silencing, whereas sustained transgene expression may be obtained following transfer of minicircles. [19] [20] [21] 39 The persistence of transgene expression following hydrodynamic transfer of minicircles and the sharp particles. The discrepancy between the transgene DNA copy numbers in the whole liver and in PC at the 1 h time point may be explained by the presence of significant amounts of transgene DNA in the extracellular space. Following hydrodynamic gene transfer, intracellular transgene DNA is trapped within macropinocytotic vesicles and in the cytoplasm of hepatocytes. [40] [41] [42] [43] Therefore, the sharp drop of transgene DNA copy numbers between 1 and 24 h after hydrodynamic gene transfer most likely corresponds to the degradation of minicircle DNA before it reaches the nucleus. Whereas human apo A-I plasma levels at day 35 were significantly higher following adenoviral transfer with 5 Â 10 10 particles than after hydrodynamic transfer with 20 mg of minicircles, copy numbers in PC at day 35 after transfer were similar. We speculate that chromatin assembly and DNA supercoiling of the episomal DNA may differ following gene transfer of minicircles and after adenoviral transfer. Since chromatin assembly and DNA supercoiling affect interactions between promoter and enhancers, 44 this may explain differences in transgene expression.
Whereas mature hepatocytes in adults divide at low frequency, cell division in PC occurs more frequently in children. Therefore, episomal replication of minicircles would be a desirable feature for correction of inherited liver disorders of metabolism and coagulation in children. Minicircles containing an SV40 origin of replication and an SMAR were not episomally replicative following partial hepatectomy in the current study. These data are in line with observations of Papapetrou et al. 45 who showed that 4 weeks after transduction of human hematopoietic progenitor cells with a plasmid containing an SMAR, DNA was retained in less than 1% of the transduced cells. In contrast, mitotic stability of an episomal vector containing a human SMAR has been shown in in vitro studies. 46 Furthermore, spermmediated gene transfer of plasmids containing an SMAR resulted in genetically modified pig fetuses. 47 The ATrich structure of the SMAR may induce unwinding of the SV40 origin of replication and may stimulate replication of the vector. 46 An upstream transcription running into the SMAR is strictly required for episomal replication. 48 More recently, it has been demonstrated that an SMAR may confer episomal replication in the absence of an SV40 origin of replication. 49 The discrepancy of different reports on in vivo replication of SMAR containing episomes in vivo may be explained by differences in the specific cell types investigated in these studies.
In conclusion, in this direct comparative study of 22 hepatocyte-specific expression cassettes, the combination of the DC172 promoter and two copies of the HCR-1 induces the highest transgene expression following hydrodynamic and adenoviral transfer. Hydrodynamic gene transfer of minicircles containing this most potent expression cassette persistently induces physiological human apo A-I and human FIX levels in C57BL/6 mice. The high correlation between expression levels after hydrodynamic and adenoviral transfer suggests that the combination of the DC172 promoter and two copies of the HCR-1 may also be optimal for other modes of gene transfer.
Materials and methods

Construction of expression cassettes for hepatocytedirected overexpression of human apo A-I
The construction of the reference expression cassette AT.gA-I.E 4 and of the expression cassette E 4 .AT.gA-I has been described previously. 8 AT.gA-I.E 4 contains a 1.5 kb human AT promoter upstream of the genomic human apo A-I (gA-I) sequence and four copies of the 154 bp human apo E enhancer (E 4 ). E 4 .AT.gA-I contains the same elements but the four copies of the human apo E enhancer are upstream of the AT promoter.
The DC190 promoter 29 (728 bp) containing a 520 bp human albumin promoter and two copies of the 99 bp prothrombin enhancer and the DC172 promoter (1.272 kb) consisting of a 890 bp human AT promoter and two copies of the 160 bp a 1 -microglobulin enhancer were obtained from Dr SH Cheng (Genzyme, Framingham, MA, USA). A 790 bp synthetic LSP consisting of the 475 bp thyroid hormone-binding globulin promoter and two copies of the 96 bp bikunin/a 1 -microglobulin enhancer was a kind gift of Dr A Amalfitano (Michigan State University, MI, USA). To facilitate construction of vectors containing the DC190 promoter, the DC172 promoter or the LSP promoter, a polylinker containing a ClaI, SpeI, BamHI, EcoRI, XbaI, NaeI and SalI site was cloned into pTG14681 50 (Transgène SA, Strasbourg, France). pTG14681 was linearized with EcoRI and SalI and an oligocloning was performed using the oligonucleotides 14681-for 5 0 -AATTACCGGTGCACATCGATT GCAACTAGTCAGTGGATCCGAACGAATTCTCGATC TAGAGTACGCCGGCG-3 0 and 14681-rev 5 0 -TCGACGC CGGCGTACTCTAGATCGAGAATTCGTTCGGATCCAC TGACTAGTTGCAATCGATGTGCACCGGT-3 0 to generate pTG14681-oligo.
The plasmid pTG14681-DC190.gA-I, containing the DC190 promoter upstream of the genomic human gA-I and the SV40 splice/polyadenylation site was constructed by first ligating the DC190 promoter, obtained by ClaI and SpeI digestion of pSV2-HPrT(2)HSAHIAGAL (Genzyme), into the corresponding restriction sites of pTG14681-oligo. Subsequently, the genomic human gA-I (1947 bp), obtained by EcoRI and XbaI digestion from pUC19-gA-I, 5 was cloned into the corresponding restriction sites to generate pTG14681-DC190.gA-I. Two copies of the 154 bp human apo E enhancer were obtained by EcoRI and HindIII restriction from pUC19-2xapoE 5 and were ligated into the blunted SalI restriction site of pTG14681-DC190.gA-I to construct pTG14681-DC190.gA-I.E 2 . Four copies of the human apo E enhancer Adenoviral and hydrodynamic transfer F Jacobs et al were obtained from pUC19-8xapoE 8 by BamHI digestion. To construct pTG14681-DC190.gA-I.E 4 the same strategy was followed as for pTG14681-DC190.gA-I.E 2 .
The DC172 promoter was obtained by ClaI and SpeI digestion from pSV2A1MB(2)A1AT-HI-AGAL (Genzyme) whereas the LSP promoter was obtained by BamHI digestion of pShuttle-LSP.pA. 51 Similar strategies as for the DC190 promoter containing constructs were used to generate pTG14681-DC172.gA-I, pTG14681-DC172.gA-I.E 2 , pTG14681-DC172.gA-I.E 4 , pTG14681-LSP.gA-I, pTG14681-LSP.gA-I.E 2 and pTG14681-LSP.gA-I.E 4 .
The 774 bp HCR-1 was obtained from human genomic DNA by Hotstar Taq PCR amplification using the primers HCR-for 5 0 -GGTACCCTGCAGGCTCAGAGGC ACACAGG-3 0 and HCR-rev 5 0 -GGTACCTCTAGAGGA GCCTGACCAACATGGTG-3 0 and cloned by T4 DNA ligase into pGEM-T-easy. The obtained sequence was identical with the published sequence. The HCR-1 fragment obtained by EcoRI restriction from pGEM.HCR1 was blunted. This blunted fragment was used to generate pTG14681-AT.gA-I.HCR, pTG14681-AT.gA-I.HCR 2 , pTG14681-AT.gA-I.HCR 4 , pTG14681-HCR.AT. gA-I, pTG14681-HCR 2 .AT.gA-I, pTG14681-DC172.gA-I. HCR 2 and pTG14681-DC172.gA-I.HCR 4 .
Bac clone RP11-113D19 containing the 2.0 kb SMAR from the 5 0 region of the human interferon-b gene was kindly provided by Dr Pieter De Jong (Children's Hospital Oakland Research Institute, CA, USA). This clone of 162 kb consists chromosome locus 9p21.2-22.3. To isolate this SMAR for cloning purposes a PCR with Hotstar Taq polymerase (Qiagen, Venlo, the Netherlands) was performed on this Bac clone using the primers SMAR-for 5 0 -GGCAAAGAAGTGCAAGACTGTTACCC-3 0 and SMAR-rev 5 0 -GGAAGCACAATGCCCAGATG GGTTC-3 0 . Sequencing of multiple clones, generated by independent PCRs, was performed to exclude clones that have mutations introduced during PCR amplification. Subsequent cloning steps led to the generation of pTG14681-E 4 .AT.gA-I.SMAR. Transcription in this construct runs into the SMAR since the endogenous polyadenylation site of the genomic human gA-I has been removed.
To construct vectors containing the human apo A-I cDNA sequence instead of the genomic human gA-I, the human apo A-I cDNA was isolated from pACplpAcDNA 52 by digestion with EcoRI and HindIII and was used to generate pTG14681-AT.cDNA.E 4 . A 251 bp sequence of the genomic human gA-I containing the complete 5 0 -UTR including the first apo A-I intron was subcloned to generate pTG14681-AT.A-I intron.cDNA.E 4 . Multiple sublconing steps using a truncated human FIX intron 12, 53, 54 isolated from pGEM-FIX-intron by ClaI and NotI digestion led to the formation of pTG14681-AT.FIX intron.cDNA.E 4 .
Production of infectious plasmids and large-scale production of adenoviral vectors were performed as described previously. 24 Construction of vectors for production of minicircle DNA occurred as described previously by Chen et al. 39 The plasmid pP2fC31, which contains two copies of the fC31 integrase of the Streptomyces temperate phage under the control of an arabinose inducible promoter (araBAD, Invitrogen, Carslbad, CA, USA) and one copy of the endonuclease I-SceI gene under control of the same promoter, was kindly provided by Dr MA Kay (Stanford University School of Medicine, Stanford, CA, USA). After generation of the plasmids pP2fC31-DC172.gA-I.HCR 2 and pP2fC31-DC172.gA-I.SMAR.HCR 2 .SV40ori, the minicircles mcDC172.gA-I.HCR 2 and mcDC172.gA-I.SMAR.HCR 2 .SV40ori were produced as described by Chen et al.
39
Construction of an expression cassette for hepatocytedirected overexpression of human factor IX The human FIX cDNA was kindly provided by Dr Monica Lusky (Transgène SA). To generate pTG14681-DC172.A-I intron.FIX.HCR 2 , the genomic human gA-I was removed from pTG14681-DC172.gA-I.HCR 2 by an EcoRI-XbaI restriction followed by a blunt self-ligation, generating pTG14681-DC172.HCR 2 . Subsequently, the 1.8 kb human FIX cDNA was excised from pTG15113-FIX (Transgène) by XmaI and ligated into the NgoMIV site of pTG14681-DC172.HCR 2 , resulting in pTG14681-DC172.FIX.HCR 2 . Finally, the 251 bp apo A-I intron was ligated upstream of the FIX cDNA using EcoRI and XbaI, thus generating pTG14681-DC172.A-I intron. FIX.HCR 2 . Minicircles expressing human FIX under control of the DC172 promoter and two copies of HCR-1 (mcDC172.A-I intron.FIX.HCR 2 ) were produced as described by Chen et al.
Animal experiments
All experimental procedures in animals were performed in accordance with protocols approved by the Institutional Animal Care and Research Advisory Committee. C57BL/6 mice were obtained from the specific pathogenfree animal facility at the Center for Molecular and Vascular Biology. A dose of 5 Â 10 10 adenoviral particles was administered in 200 ml by tail vein injection. Vectors were diluted in isotonic saline buffer (10 mM Tris-HCl (pH 7.4), 137 mM NaCl, 5 mM KCl, 1 mM MgCl 2 ). Hydrodynamic gene transfer of plasmids or minicircles was performed by tail vein injection of the DNA in a volume of 90 ml g À1 body weight in 5-7 s. A 70% partial hepatectomy was performed as described by Higgins and Anderson. 55 After Nembutal anesthesia (40-70 mg kg À1 ), 5-0 silk suture ligatures were secured around the base of the median and left lateral hepatic lobes. The lobes were resected and snap-frozen in liquid nitrogen.
Human apo A-I ELISA
Human apo A-I levels were determined by sandwich enzyme-linked immunosorbent assay (ELISA) as described previously. 5 Human FIX ELISA Human FIX expression was determined in citrated plasma using the commercial Asserachrom IX:Ag kit (Diagnostica Stago, Asnières sur Seine, France) according to the manufacturer's instructions.
Quantification of human apo A-I transgene DNA in the liver
Quantification of human apo A-I DNA copy number per diploid genome was performed by real-time PCR as described. 56 The human apo A-I DNA copy number was normalized to the copy number of the Prion Protein (PrP) gene.
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Isolation of parenchymal and nonparenchymal liver cells
Parenchymal and NPC were isolated as described before. 57 Quantification of liver inflammation following adenoviral and hydrodynamic transfer After euthanasia, livers were fixed overnight in 1% paraformaldehyde and embedded in paraffin. Seven mm thick sections were stained with rabbit anti-human CD3 antibody (DakoCytomation, Glostrup, Denmark) or rat anti-mouse neutrophil antibody clone 7/4 (AbD Serotec, Oxford, UK) 58 followed by incubation with an anti-rabbit Envision secondary antibody or a peroxidase-labeled donkey anti-rat secondary antibody (AbD Serotec), respectively. 3,3
0 -diaminobenzidine (Sigma-Aldrich, Bornem, Belgium) was used as chromogen. Absolute numbers of inflammatory cells per square millimeter were quantified in a blinded fashion by computerassisted image analysis using KS300 software (Carl Zeiss, Zaventem, Belgium).
Statistical analysis
Data are expressed as means±standard error of the mean (s.e.m.). Comparison of human apo A-I levels between different constructs was performed by analysis of variance followed by Dunnett's multiple comparisons test (GraphPad Software, San Diego, CA, USA). Liver inflammation data were compared to baseline by analysis of variance followed by Dunnett's multiple comparisons test. Human apo A-I transgene DNA levels were compared by Mann-Whitney test. A two-sided P-value of less than 0.05 was considered statistically significant.
